Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Aeon Biopharma Inc (AEON)

Aeon Biopharma Inc (AEON)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 21,745
  • Shares Outstanding, K 25,303
  • Annual Sales, $ 0 K
  • Annual Income, $ -39,220 K
  • EBIT $ -11 M
  • EBITDA $ -11 M
  • 60-Month Beta 0.74
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -4.80
  • Most Recent Earnings $-3.72 on 03/30/26
  • Next Earnings Date 05/13/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $3.75
  • Growth Rate Est. (year over year) +26,540.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8134 +8.19%
on 04/10/26
1.3295 -33.81%
on 03/27/26
-0.2300 (-20.72%)
since 03/13/26
3-Month
0.8134 +8.19%
on 04/10/26
1.4500 -39.31%
on 02/23/26
-0.2275 (-20.54%)
since 01/14/26
52-Week
0.3788 +132.31%
on 04/17/25
1.4500 -39.31%
on 02/23/26
+0.4700 (+114.63%)
since 04/14/25

Most Recent Stories

More News
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711

IRVINE, Calif., April 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as...

AEON : 0.8800 (+2.40%)
AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards

IRVINE, Calif., April 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as...

AEON : 0.8800 (+2.40%)
AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program

– Announced positive initial comparative analytical results, confirming identical amino-acid sequencing and highly similar functional characteristics to BOTOX ® –  – Reported positive FDA...

AEON : 0.8800 (+2.40%)
AEON Biopharma Announces FDA Feedback Following BPD Type 2a Meeting for the ABP-450 Biosimilar Program

FDA provided constructive feedback on Company’s analytical similarity strategy under the 351(k) biosimilar pathway  Company continues to execute its analytical program and plans to request...

AEON : 0.8800 (+2.40%)
AEON Biopharma Appoints John Bencich as Chief Financial Officer

IRVINE, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as...

AEON : 0.8800 (+2.40%)
AEON Biopharma Abstract Accepted for Presentation at 2026 American Academy of Neurology (AAN) Annual Meeting

IRVINE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as...

AEON : 0.8800 (+2.40%)
AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions

-  AEON confirmed that earlier today it held its BPD Type 2a Meeting with the FDA, in line with prior guidance, and is now awaiting official meeting minutes - - Separately, AEON shareholders today...

AEON : 0.8800 (+2.40%)
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711

IRVINE, Calif., Dec. 19, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company seeking accelerated and full-label U.S. market...

AEON : 0.8800 (+2.40%)
AEON Biopharma Announces Execution of Exchange Agreement with Daewoong

- AEON and Daewoong Pharmaceutical have executed definitive documentation to exchange $15 million of notes plus accrued interest into new equity, $1.5 million of new notes due 2030, and a cash-exercise...

AEON : 0.8800 (+2.40%)
AEON Biopharma Announces First Closing of PIPE Investment and Provides Update on FDA Type 2a Meeting Scheduling

-  First closing of PIPE resulted in ~$1.79M in proceeds - - FDA BPD Type 2a meeting now scheduled for January 21, 2026 - IRVINE, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc....

AEON : 0.8800 (+2.40%)

Business Summary

AEON Biopharma Inc. is a clinical-stage biopharmaceutical company. It focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions. AEON Biopharma Inc., formerly known as Priveterra Acquisition Corp., is based in IRVINE, Calif.

See More

Key Turning Points

3rd Resistance Point 0.9303
2nd Resistance Point 0.9003
1st Resistance Point 0.8799
Last Price 0.8800
1st Support Level 0.8295
2nd Support Level 0.7995
3rd Support Level 0.7791

See More

52-Week High 1.4500
Fibonacci 61.8% 1.0408
Fibonacci 50% 0.9144
Last Price 0.8800
Fibonacci 38.2% 0.7880
52-Week Low 0.3788

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.